Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Acompanhamento de longo prazo para estudos de reparo da válvula mitral CTSN

17 de novembro de 2026 atualizado por: Annetine Gelijns, Icahn School of Medicine at Mount Sinai

Acompanhamento de longo prazo para participantes de: Avaliação dos resultados após reparo/substituição da válvula mitral em SMR e intervenções cirúrgicas para ensaios de MMR

This study is a continuation of two previous studies --- the Severe Ischemic Mitral Regurgitation (SMR) Trial (NCT00807040) and the Moderate Ischemic Mitral regurgitation (MMR) Trial (NCT00806988) --- to learn more about patients' health 5-10 years after their mitral valve surgeries. The investigators will collect long-term health information on SMR and MMR trial participants using electronic medical records, patient and/or family input, public records, and healthcare- and vital status-related databases.

Visão geral do estudo

Descrição detalhada

This study is a continuation of two CTSN randomized trials --- the Severe Ischemic Mitral Regurgitation (SMR) Trial (NCT00807040) and the Moderate Ischemic Mitral regurgitation (MMR) Trial (NCT00806988) --- for the purpose of assessing the long-term outcomes of the index surgical therapies. Key clinical outcomes will be collected utilizing electronic medical records, patient and/or family input, public records, and healthcare- and vital status-related databases. Extended follow-up data will be obtained on up to 199 SMR and 270 MMR trial participants, who were alive at their 2-year follow-up evaluation. Patients will be followed for a minimum of 5 years and up to 10 years after randomization (the time of index surgical procedure). This follow-up data collection will be conducted by the Cardiothoracic Surgical Trials Network (CTSN) primarily utilizing the minimal PHI necessary to link data obtained from the MMR and SMR trials to other healthcare- and/or vital status-related databases.

Because the design of surgical trials for ischemic mitral regurgitation that would use mortality as a primary endpoint requires the enrollment of thousands of patients, the selected primary endpoint for the CTSN SMR and MMR trials was an echocardiographic measure of left ventricular remodeling. Secondary endpoints included, among others, survival, adverse events, readmissions and costs over a 2-year period. The SMR trial showed no difference in left ventricular reverse remodeling, but the rate of moderate or severe mitral regurgitation recurrence was significantly higher with mitral valve repair, resulting in more heart failure-related adverse events and cardiovascular admissions. Longer-term follow-up will be critical to assess whether this observed trend amongst SMR patients will continue and whether a survival difference will manifest over time. In moderate ischemic mitral regurgitation, mitral valve repair provided a more durable correction of mitral regurgitation than coronary artery bypass grafting (CABG) alone, but repair did not improve survival or reduce overall adverse events or readmissions, and was associated with an early hazard of neurological and supraventricular arrhythmic events. Longer-term follow-up of MMR patients will provide insights into whether the higher degree of recurrent mitral regurgitation with CABG alone will be associated with differences in adverse events, readmissions and survival. Additionally, the benefits of alternative surgical treatments for ischemic mitral regurgitation, which have differential upfront risks and costs, will likely extend beyond 2 years. Cost-effectiveness analysis will delineate the long-term cost-benefit trade-offs between mitral valve repair versus replacement for SMR, and of CABG with repair versus CABG alone for MMR, which should inform surgical decision making, and examine how differences in life expectancy and risk profiles of different patient groups affect cost-effectiveness over time. This extended follow-up should provide important clinical and health policy insights.

Tipo de estudo

Observacional

Inscrição (Real)

368

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

      • Québec, Canadá, G1V 4G5
        • Institut Universitaire de Cardiologie de Quebec (Hopital Laval)
    • Alberta
      • Edmonton, Alberta, Canadá, T6G2B7
        • University of Alberta Hospital
    • Ontario
      • Toronto, Ontario, Canadá, M5B 1W8
        • Saint Michael's Hospital
      • Toronto, Ontario, Canadá, M4N 3M5
        • Sunnybrook Health Science Centre
      • Toronto, Ontario, Canadá, M5B 1W8
        • Toronto General Hospital
    • Quebec
      • Montreal, Quebec, Canadá, H1T 1C8
        • Montreal Heart Institute
      • Montreal, Quebec, Canadá, H2W 1T8
        • Centre Hospitalier de l'Université de Montréal
      • Montreal, Quebec, Canadá
        • Hôpital du Sacré-Cœur de Montréal
    • California
      • Los Angeles, California, Estados Unidos, 90033
        • University of Southern California
    • Georgia
      • Atlanta, Georgia, Estados Unidos, 30308
        • Emory University
    • Maryland
      • Baltimore, Maryland, Estados Unidos, 21201
        • University of Maryland
      • Bethesda, Maryland, Estados Unidos, 20814
        • Suburban Hospital
    • Massachusetts
      • Boston, Massachusetts, Estados Unidos, 02115
        • Brigham and Women's Hospital
    • New York
      • New York, New York, Estados Unidos, 10032
        • Columbia University Medical Center
      • The Bronx, New York, Estados Unidos, 10467
        • Montefiore Einstein Heart Center
    • North Carolina
      • Asheville, North Carolina, Estados Unidos, 28801
        • Mission Hospital
      • Durham, North Carolina, Estados Unidos, 27710
        • Duke University
      • Greenville, North Carolina, Estados Unidos, 27834
        • East Carolina Heart Institute
    • Ohio
      • Cleveland, Ohio, Estados Unidos, 44195
        • Cleveland Clinic Foundation
      • Columbus, Ohio, Estados Unidos, 43210
        • Ohio State University
    • Pennsylvania
      • Philadelphia, Pennsylvania, Estados Unidos, 19104
        • University of Pennsylvania
    • Texas
      • Plano, Texas, Estados Unidos, 75093
        • Baylor Research Institute
    • Virginia
      • Charlottesville, Virginia, Estados Unidos, 22908
        • University of Virginia Health Systems
      • Falls Church, Virginia, Estados Unidos, 22042
        • Inova Heart and Vascular Institute

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Método de amostragem

Amostra Não Probabilística

População do estudo

Randomized patients in the MMR and SMR trials who were still alive at 2 years after the index cardiac surgical intervention

Descrição

Inclusion Criteria:

  • Randomized patients in the MMR and SMR trials who were still alive at 2 years after the index cardiac surgical intervention

Exclusion Criteria:

  • Patients participating in the MMR and SMR trials who withdrew consent prior to the 2-year follow-up evaluation

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Modelos de observação: OTHER
  • Perspectivas de Tempo: OTHER

Coortes e Intervenções

Grupo / Coorte
Intervenção / Tratamento
SMR MV Repair

This group of patients had been randomized in the SMR study to mitral valve repair with annuloplasty ring.

Participants underwent mitral valve repair with annuloplasty and a sub-valvular procedure for severe tethering.

Outros nomes:
  • Reparação da Valva Mitral
MV Replacement

This group of patients had been randomized in the SMR study to mitral valve replacement.

Participants underwent mitral valve replacement and complete preservation of the sub-valvular apparatus.

Outros nomes:
  • Substituição da Válvula Mitral
MMR MV Repair

This group of patients had been randomized in the MMR study to mitral valve repair with annuloplasty ring.

Participants underwent mitral valve repair with annuloplasty and a sub-valvular procedure for severe tethering.

Outros nomes:
  • Reparação da Valva Mitral
CABG

This group of patients had been randomized in the MMR study to receive CABG

Participants underwent coronary artery bypass grafting

Outros nomes:
  • Enxerto de Revascularização do Miocárdio

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Survival
Prazo: up to 10 years post-surgery (at the time of registry data transfer)

All-cause mortality will be assessed.

up to 10 years post-surgery (at the time of registry data transfer)

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Repeat Cardiac Interventions for MR
Prazo: up to 10 years post-surgery (at the time of registry data transfer)

Repeat cardiac interventions for MR in particular will be determined for the duration of follow-up and will be analyzed using a time-to-event analysis.

up to 10 years post-surgery (at the time of registry data transfer)
Hospital Costs
Prazo: up to 10 years post-surgery (at the time of registry data transfer)

Hospital costs will be calculated for the duration of follow-up utilizing the minimum PHI necessary to link the CTSN databases to other databases (e.g., Vizient, CMS Medicare, and Canadian Province databases). Cost data will be extracted from the Vizient operational database system for member sites or national payer or state-wide databases. Dates of charges and revenue codes will be used to match the cost data with data on readmissions. We will estimate costs including center-specific ratios of cost to charges. These ratios will be based on the annual Medicare costs reports submitted annually by participating study sites to Medicare. These data will be used to impute data for patients treated at hospitals, which are non-Vizient members.

up to 10 years post-surgery (at the time of registry data transfer)
Cost Effectiveness
Prazo: up to 10 years post-surgery (at the time of registry data transfer)

Cost Effectiveness using Incremental Cost Effectiveness Ratio and Net Health Benefit parameters. The primary objective of the cost-effectiveness analysis (CEA) is to estimate the incremental cost-effectiveness ratio (ICER) of the intervention under investigation as compared to the study-defined alternative. This ratio measures the ratio of the difference in costs and outcomes between the two study arms for each trial, with outcomes measured as life-years. We will also compute net health benefits (NHB) as an alternative way of looking at cost-effectiveness. This parameter compares the incremental effectiveness of an intervention with the minimum health effect that society would demand in return for the investment; i.e., with the health produced by investing at the societal ceiling cost-effectiveness ratio.

up to 10 years post-surgery (at the time of registry data transfer)

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Investigadores

  • Cadeira de estudo: Richard Weisel, MD, Toronto General Hospital
  • Investigador principal: Annetine C Gelijns, PhD, Icahn School of Medicine at Mount Sinai

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

3 de maio de 2017

Conclusão Primária (Estimado)

31 de julho de 2027

Conclusão do estudo (Estimado)

31 de julho de 2027

Datas de inscrição no estudo

Enviado pela primeira vez

2 de fevereiro de 2017

Enviado pela primeira vez que atendeu aos critérios de CQ

22 de fevereiro de 2017

Primeira postagem (Real)

28 de fevereiro de 2017

Atualizações de registro de estudo

Última Atualização Postada (Real)

20 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

17 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever